Medable Inc. to Present at the Biotech Showcase Annual Conference on January 10, 2018 Print
By GLOBE NEWSWIRE   
Wednesday, 03 January 2018 04:00

PALO ALTO, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE)

PALO ALTO, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Medable Inc., the leading app and analytics platform for healthcare, today announced that Medable CEO Dr. Michelle Longmire will talk about “The Future of Direct-to-Patient Digital Platforms” at Biotech Showcase 2018, to be held January 8–10 during the J.P. Morgan Annual Healthcare Conference.

Michelle Longmire, MD, CEO of Medable Inc.
Digital health pioneer Dr. Michelle Longmire, CEO of Medable Inc., will speak at Biotech Showcase, about the human "digitome", reproducible digital signatures of health and disease.


A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/9d6f2072-8f71-4858-b349-f8986f016bae

Dr. Longmire’s presentation will be on January 10, 2018 at 1:30 PM (PST).  The presentation will be held at the Hilton San Francisco Union Square, Cyril Magnin III, 4th Floor, in San Francisco.

Dr. Longmire will talk about Medable's industry leading direct-to-patient platform, and reveal how Medable’s platform enables health data to be intelligently aggregated across the first fully digital representation of human health, the human “digitome,” from which reproducible digital signatures of health and disease can be derived for digital biomarkers and digital therapeutics. Recently, Duke University and the University of Pennsylvania announced that they adopted Medable's platform for direct-to-patient disease management apps and clinical studies.  Medable is the only platform that enables direct-to-patient with an enterprise platform useable by health experts without developers. 

Prior to Medable, Dr. Longmire trained in dermatology at Stanford University where she studied epigenetics.  While working in the Stanford lab, she studied how the human genome is expressed in dermatological diseases. She began to understand the shortcomings of clinical research and how the data captured from patients in a clinical setting lacks the real world context needed to tell us the whole story of a patient's health.  She co-founded Medable in 2014 to develop a purpose-built platform for healthcare that captures data directly from patients.  In 2017, privately-held Medable experienced 10X revenue growth, tripled its number of employees, introduced two new products and

made partnership deals with Fortune 500 healthcare companies and

Error. Page cannot be displayed. Please contact your service provider for more details. (19)

top medical research hospitals, who collectively serve over 15 million patients and
conduct 6,000 clinical trials. Based on current market demand, Dr. Longmire predicts that Direct-to-Patient healthcare will continue to see rapid market adoption.  

“There is tremendous need to decentralize healthcare and research to enable better, real world data capture and anytime, anywhere delivery of care,” said Longmire. “Our platform is defining Direct-to-Patient and making mobile data capture as easy to use by healthcare experts as a stethoscope. We are enabling a fundamental shift in how healthcare is delivered and disease is studied.”   

Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences, the J.P. Morgan Annual Healthcare Conference.

About Medable Inc.

Medable was founded in 2014 to enable healthcare technology to be as seamless, integrated, and adaptive as the human body. Medable is transforming healthcare by enabling patient generated data to drive healthcare delivery, clinical research, and personalized and predictive medicine. 

Website:  www.medable.com

Follow Medable on Twitter: @Medableinc

Gary Poole, PR Director gary@medable.com

Primary Logo




BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
  BMR:1